Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with subcutaneous injections achieving disease control in people with paroxysmal nocturnalhaemoglobinuria as shown in COMMODORE 3 study in China8Basel, 3 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it will present new data from its industry-leading haematology portfolio at the 64th American Society of Hematology (ASH) Annual Meeting from 10-13 December 2022. The data to be presented span numerous blood diseases, including haemophilia A, paroxysmal nocturnal haemoglobinuria (PNH), and various types of blood cancers, including non-Hodgkin lymphoma (NHL) and multiple myeloma. Roche ’s approved and investigational medicines will be featured in more than 50 abstracts, including more than 15 oral presentations.“We continually strive to improve patient outcomes by exploring new treatment options across blood disorders, such as lymphomas an...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news